Month: September 2021

Further segregation of business operations and establishment of subsidiaries Following the decision made by the board of directors of Skeljungur hf. to enter into exclusive negotiations with a group of buyers regarding P/F Magn, and in accordance with an announcement of last 11 August regarding the decision to place part of Skeljungur hf. real estate in formal divestment process, the board of directors of the Company has now decided to further sharpen the points of focus of the Company’s business activities by establishing two new and independent subsidiaries. The proposed new subsidiaries are the following:A company for retail services: The work of this company will focus on services to individuals, including the operation of Orkan’s service stations, Extra, 10-11, the Löður car wash stations, and the Lyfsalinn and Lyfjaval pharmacies,...

GRAND BAIE, Mauritius, Sept. 09, 2021 (GLOBE NEWSWIRE) — Alphamin Resources Corp. (TSXV: AFM, JSE AltX: APH, “Alphamin” or “the Company”) announced today that, subject to regulatory approval, it has granted stock options to acquire an aggregate of 4,000,000 common shares to directors and employees of Alphamin’s subsidiaries under its stock option plan. Each option is exercisable for a seven year term to acquire one common share at a price of C$0.78 per share. The options granted vest over differing periods of between fifteen months and four years from the date of grant. FOR MORE INFORMATION, PLEASE CONTACT: Maritz Smith                                CEO                        Alphamin Resources Corp.                        Tel: +230 269 4166E-mail: msmith@alphaminresources.com Neither the TSX Venture Exchange nor its regulation...

– Increasing Global Awareness of Innovative Suprachoroidal Injection Platform – ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today it has agreed to expand the territories covered by its exclusive license agreement with Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies. As now amended, the licensed territory for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) has been expanded from Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea to also include Australia, New Zealand, India and the ASEAN Countries (Brunei, Cambodia, Indonesia,...

– Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered into an agreement with Vizient to offer XENLETA, which treats community-acquired bacterial pneumonia (CABP), as a contracted product to Vizient’s Pharmacy Network Program. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $110 billion in annual purchasing volume, to improve patient outcomes and lower costs. Nabriva CEO Ted Schroeder commented, “We are excited by Vizient’s...

DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel (cannabidiol formulated in a transdermal gel [ZYN002]) in children and adolescents with autism spectrum disorder (ASD) over a longer term, 38-week treatment period. These data were presented as an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 being held virtually from September 9-10, 2021. A copy of the presentation is available on the Zynerba corporate website at http://zynerba.com/publications/. Helen (Honey) Heussler, MBBS FRACP MRCPCH, DM, Associate Professor,...

Lantronix’s IoT Technology Integral to Development of Point-of-Care Medical Diagnostic Devices IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM) offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware, provides IoT technologies that are driving the development of secure point-of-care (POC) connected healthcare applications for remote clinical, veterinary and environmental testing. “In today’s world of critical medical equipment needs, we at Lantronix are dedicated to providing IoT and intelligent edge systems that enable our clients to deliver secure connected healthcare solutions for the remote diagnostics and treatment of patients,”...

VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | OTCQB:LIACF | Frankfurt:5LA1) is pleased to announce positive pre-concentration upgrading results from Tonopah Lithium Claims (“TLC”) claystone mineralization using Falcon continuous gravity concentrators with 88% of Lithium concentrated in 60% of the original mass – an upgrading factor of approximately 1.5. Upgrading Highlights:Gravity concentration test work by TECMMINE, in consultation with Sepro Mineral Systems of Lima Peru, yielded excellent results using continuous gravity Falcon (”Falcon C”) concentrators. Test work rapidly upgraded samples of TLC mineralization from 1,098 ppm Li to 1,671 ppm Li by retaining 88% of the lithium in 60% of the mass. On-going test work to further optimize...

VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) — Extreme Vehicle Battery Technologies Corp. (the “Company” or “EV Battery Tech”) (CSE: ACDC), together with its subsidiary IoniX Pro Battery Technologies (“IoniX Pro”), is pleased to present its Blockchain Power Management System and Application, Smart CommandTM (“Smart Command”). Smart Command is based on cutting-edge blockchain technology that works with EV Battery Tech’s patented Battery Management System (BMS) to deliver a user-friendly computer and phone application (the “App”), that delivers revolutionary monitoring, maintenance and machine learning features. The Smart Command system and App will be integrated into the entire IoniX Pro suite of Energy Storage System (ESS) products, allowing for complete power management and smart grid communications. This will...

Final patient visit has been completed in its Phase 2 RESCUE-ALS study; study close-out activities have commenced 90% of eligible patients are continuing to be treated under a long-term open label extension Interim blinded efficacy data after 9-months of treatment with CNN-Au8®, a catalytically-active gold nanocrystal suspension, showed absolute improvement from baseline in neurophysiology endpoints as compared to progressive worsening seen in published data setsSALT LAKE CITY, Sept. 09, 2021 (GLOBE NEWSWIRE) —  Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat cellular energetic failure, announced the final patient visit has been...

–  Study has now enrolled a total of nine patients across low-dose and high-dose cohorts–  On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 cohort in October 2021 NEW YORK, and DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) — Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced dosing of the first Type I, or early infantile, patient in the low-dose cohort of its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis. No serious adverse events considered by the investigators to be related to AXO-AAV-GM1 have been observed following...